Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA. ...

With Novo Nordisk’s semaglutide patent set to expire in China in 2026, local companies are readying generics to grasp market ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly ...

Adults with type 1 diabetes and obesity using tirzepatide in a real-world setting had improvements in glycemic control and a reduction in body weight at 6 months, researchers reported. Tirzepatide ...

Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.

With one in four British adults now obese, patients worry that soaring costs of Mounjaro, driven by pressure from Trump, risk undoing life-changing progress.

The drugs have been shown to have no benefit for the majority of patients. Also, researchers found an increased risk of death in some women, according to lead author Dr. Borja Ibáñez, scientific ...

Medical experts discuss whether GLP-1 medications, including Mounjaro and Zepbound, could become comprehensive treatments for ...

Scientists are racing to improve weight loss treatments beyond drugs like Ozempic and Wegovy, which are effective but plagued by nausea, bone loss, and weight regain. Tufts University chemists have ...

Combining tirzepatide injections with hormone replacement therapy leads to significantly greater fat loss in many more women ...

Christina Parfitt is wanted in connection with an investigation into the sale of fake Wegovy, Mounjaro and retatrutide.

Treatment with the anti-obesity medications can reduce health risks for patients with heart failure by more than 40%. These ...